text: peg precipitation + ultracentrifugation

text: live

text: SARS-CoV-2: wastewater surveillance

text: collection site records

text: qiagen qiaamp viral rna mini kit

text: USA: Kentucky

text: wastewater

text: wastewater metagenome

text: Covid concetration

text: Crassphage

text: 2282874, 2493547

text: Bio Rad ddPCR custom

text: Copies/L

text: 24 hours

text: raw wastewater

text: sewer pipeline

text: composite

text: Copies/L

text: Copies/uL

text: no

text: Bio Rad ddPCR custom

text: Copies/L

text: Copies/uL

text: no

text: Bio Rad ddPCR custum


status: PUBLIC

text: peg precipitation + ultracentrifugation

tag: attribute

characteristic: Concentration Method (group)

characteristic: External Id

text: Kentucky State Cabinet for Health and Family Services

characteristic: INSDC center name

characteristic: INSDC first public

characteristic: INSDC last update

text: live

characteristic: INSDC status

text: SARS-CoV-2: wastewater surveillance

characteristic: NCBI submission model

characteristic: NCBI submission package

characteristic: SRA accession

characteristic: Ww Population

text: collection site records

characteristic: Ww Population Source

text: qiagen qiaamp viral rna mini kit

text: USA: Kentucky

text: wastewater

text: wastewater metagenome

characteristic: organism

text: public health surveillance community-level

text: Covid concetration

characteristic: title

text: Crassphage

text: 4867, 9591

text: Bio Rad ddPCR custom

text: Copies/L

text: 24 hours

text: raw wastewater

text: sewer pipeline

text: composite

text: Copies/L

text: Copies/uL

text: no

text: Bio Rad ddPCR custom

text: Copies/L

text: Copies/uL

text: no

text: Bio Rad ddPCR custum


text: peg precipitation + ultracentrifugation

text: live

text: SARS-CoV-2: wastewater surveillance

text: collection site records

text: qiagen qiaamp viral rna mini kit

text: USA: Kentucky

text: wastewater

text: wastewater metagenome

text: Covid concetration

text: Crassphage

text: 10575, 13733

text: Bio Rad ddPCR custom

text: Copies/L

text: 24 hours

text: raw wastewater

text: sewer pipeline

text: composite

text: Copies/L

text: Copies/uL

text: no

text: Bio Rad ddPCR custom

text: Copies/L

text: Copies/uL

text: no

text: Bio Rad ddPCR custum


text: peg precipitation + ultracentrifugation

text: live

text: SARS-CoV-2: wastewater surveillance

text: collection site records

text: qiagen qiaamp viral rna mini kit

text: USA: Kentucky

text: wastewater

text: wastewater metagenome

text: Covid concetration

text: Crassphage

text: 655210, 650612

text: Bio Rad ddPCR custom

text: Copies/L

text: 24 hours

text: raw wastewater

text: sewer pipeline

text: composite

text: Copies/L

text: Copies/uL

text: no

text: Bio Rad ddPCR custom

text: Copies/L

text: Copies/uL

text: no

text: Bio Rad ddPCR custum


text: peg precipitation + ultracentrifugation

text: live

text: SARS-CoV-2: wastewater surveillance

text: collection site records

text: qiagen qiaamp viral rna mini kit

text: USA: Kentucky

text: wastewater

text: wastewater metagenome

text: Covid concetration

text: Crassphage

text: 474863, 586186

text: Bio Rad ddPCR custom

text: Copies/L

text: 24 hours

text: raw wastewater

text: sewer pipeline

text: composite

text: Copies/L

text: Copies/uL

text: no

text: Bio Rad ddPCR custom

text: Copies/L

text: Copies/uL

text: no

text: Bio Rad ddPCR custum


text: peg precipitation + ultracentrifugation

text: live

text: SARS-CoV-2: wastewater surveillance

text: collection site records

text: qiagen qiaamp viral rna mini kit

text: USA: Kentucky

text: wastewater

text: wastewater metagenome

text: Covid concetration

text: Crassphage

text: 29774715, 30866700, 33848676

text: Bio Rad ddPCR custom

text: Copies/L

text: 24 hours

text: raw wastewater

text: sewer pipeline

text: composite

text: Copies/L

text: Copies/uL

text: no

text: Bio Rad ddPCR custom

text: Copies/L

text: Copies/uL

text: no

text: Bio Rad ddPCR custum


text: peg precipitation + ultracentrifugation

text: live

text: SARS-CoV-2: wastewater surveillance

text: collection site records

text: qiagen qiaamp viral rna mini kit

text: USA: Kentucky

text: wastewater

text: wastewater metagenome

text: Covid concetration

text: Crassphage

text: 58152, 133713, 255164

text: Bio Rad ddPCR custom

text: Copies/L

text: 24 hours

text: raw wastewater

text: sewer pipeline

text: composite

text: Copies/L

text: Copies/uL

text: no

text: Bio Rad ddPCR custom

text: Copies/L

text: Copies/uL

text: no

text: Bio Rad ddPCR custum


text: Zhejiang A&F University

characteristic: INSDC secondary accession

text: live

text: Plant

text: missing

characteristic: age

text: missing

characteristic: cultivar

text: Five leaf and one heart stage

text: missing

characteristic: ecotype

text: China:Guangxi province

text: missing

characteristic: isolate

text: Phyllostachys edulis

text: biological replicate 1

characteristic: replicate

text: 4℃

characteristic: temp

text: Five leaves and one heart

characteristic: tissue

text: Plant sample from Phyllostachys edulis

text: cold

characteristic: treatment


characteristic: External Id

text: Zhejiang A&F University

characteristic: INSDC center name

characteristic: INSDC first public

characteristic: INSDC last update

text: live

characteristic: INSDC status

text: Plant

text: missing

text: missing

text: Five leaf and one heart stage

text: missing

text: China:Guangxi province

text: missing

text: Phyllostachys edulis

text: biological replicate 2

text: 4℃

text: Five leaves and one heart

text: Plant sample from Phyllostachys edulis

text: cold


text: Zhejiang A&F University

text: live

text: Plant

characteristic: NCBI submission model

characteristic: NCBI submission package

characteristic: SRA accession

text: missing

text: missing

text: Five leaf and one heart stage

text: missing

text: China:Guangxi province

text: missing

text: Phyllostachys edulis

text: biological replicate 3

text: 4℃

text: Five leaves and one heart

text: Plant sample from Phyllostachys edulis

text: cold


text: Zhejiang A&F University

characteristic: INSDC secondary accession

text: live

text: Plant

text: missing

text: missing

text: Five leaf and one heart stage

text: missing

text: China:Guangxi province

text: missing

text: Phyllostachys edulis

characteristic: organism

text: biological replicate 1

text: Five leaves and one heart

text: Plant sample from Phyllostachys edulis

characteristic: title

text: heat


text: Zhejiang A&F University

text: live

text: Plant

text: missing

characteristic: age

text: missing

characteristic: cultivar

text: Five leaf and one heart stage

text: missing

characteristic: ecotype

text: China:Guangxi province

text: missing

text: Phyllostachys edulis

text: biological replicate 2

text: Five leaves and one heart

text: Plant sample from Phyllostachys edulis

text: heat


text: Zhejiang A&F University

text: live

text: Plant

text: missing

text: missing

text: Five leaf and one heart stage

text: missing

text: China:Guangxi province

text: missing

characteristic: isolate

text: Phyllostachys edulis

text: biological replicate 3

characteristic: replicate

characteristic: temp

text: Five leaves and one heart

text: Plant sample from Phyllostachys edulis

text: heat


characteristic: External Id

text: Zhejiang A&F University

text: live

text: Plant

text: missing

text: missing

text: Five leaf and one heart stage

text: missing

text: China:Guangxi province

text: missing

text: Phyllostachys edulis

text: biological replicate 1

text: Five leaves and one heart

characteristic: tissue

text: Plant sample from Phyllostachys edulis

text: uv

characteristic: treatment


text: Zhejiang A&F University

characteristic: INSDC center name

characteristic: INSDC first public

characteristic: INSDC last update

text: live

text: Plant

text: missing

text: missing

text: Five leaf and one heart stage

text: missing

text: China:Guangxi province

text: missing

text: Phyllostachys edulis

text: biological replicate 2

text: Five leaves and one heart

text: Plant sample from Phyllostachys edulis

text: uv


text: Zhejiang A&F University

text: live

characteristic: INSDC status

text: Plant

characteristic: NCBI submission model

characteristic: NCBI submission package

text: missing

text: missing

text: Five leaf and one heart stage

text: missing

text: China:Guangxi province

text: missing

text: Phyllostachys edulis

text: biological replicate 3

text: Five leaves and one heart

text: Plant sample from Phyllostachys edulis

text: uv


text: Zhejiang A&F University

characteristic: INSDC secondary accession

text: live

text: Plant

characteristic: SRA accession

text: missing

text: missing

text: Five leaf and one heart stage

text: missing

text: China:Guangxi province

text: missing

text: Phyllostachys edulis

characteristic: organism

text: biological replicate 1

text: Five leaves and one heart

text: Plant sample from Phyllostachys edulis

text: normal


text: Zhejiang A&F University

text: live

text: Plant

text: missing

characteristic: age

text: missing

characteristic: cultivar

text: Five leaf and one heart stage

text: missing

text: China:Guangxi province

text: missing

text: Phyllostachys edulis

text: biological replicate 2

text: Five leaves and one heart

text: Plant sample from Phyllostachys edulis

characteristic: title

text: normal


text: Zhejiang A&F University

text: live

text: Plant

text: missing

text: missing

text: Five leaf and one heart stage

text: missing

characteristic: ecotype

text: China:Guangxi province

text: missing

characteristic: isolate

text: Phyllostachys edulis

text: biological replicate 3

characteristic: replicate

text: Five leaves and one heart

text: Plant sample from Phyllostachys edulis

text: normal


characteristic: External Id

text: Zhejiang A&F University

text: live

text: Plant

text: missing

text: missing

text: Five leaf and one heart stage

text: missing

text: China:Guangxi province

text: missing

text: Phyllostachys edulis

text: biological replicate 1

text: Five leaves and one heart

characteristic: tissue

text: Plant sample from Phyllostachys edulis

text: salt


text: Zhejiang A&F University

characteristic: INSDC center name

text: live

text: Plant

text: missing

text: missing

text: Five leaf and one heart stage

text: missing

text: China:Guangxi province

text: missing

text: Phyllostachys edulis

text: biological replicate 2

text: Five leaves and one heart

text: Plant sample from Phyllostachys edulis

text: salt

characteristic: treatment


text: Zhejiang A&F University

characteristic: INSDC first public

characteristic: INSDC last update

text: live

text: Plant

text: missing

text: missing

text: Five leaf and one heart stage

text: missing

text: China:Guangxi province

text: missing

text: Phyllostachys edulis

text: biological replicate 3

text: Five leaves and one heart

text: Plant sample from Phyllostachys edulis

text: salt


text: Zhejiang A&F University

text: live

characteristic: INSDC status

text: Plant

characteristic: NCBI submission model

text: missing

text: missing

text: Five leaf and one heart stage

text: missing

text: China:Guangxi province

text: missing

text: Phyllostachys edulis

text: biological replicate 1

text: Five leaves and one heart

text: Plant sample from Phyllostachys edulis


text: Zhejiang A&F University

characteristic: INSDC secondary accession

text: live

text: Plant

characteristic: NCBI submission package

text: missing

text: missing

text: Five leaf and one heart stage

text: missing

text: China:Guangxi province

text: missing

text: Phyllostachys edulis

text: biological replicate 2

text: Five leaves and one heart

text: Plant sample from Phyllostachys edulis


text: Zhejiang A&F University

text: live

text: Plant

characteristic: SRA accession

text: missing

text: missing

text: Five leaf and one heart stage

text: missing

text: China:Guangxi province

text: missing

text: Phyllostachys edulis

characteristic: organism

text: biological replicate 3

text: Five leaves and one heart

text: Plant sample from Phyllostachys edulis


text: Zhejiang A&F University

text: live

text: Plant

text: missing

characteristic: age

text: missing

characteristic: cultivar

text: Five leaf and one heart stage

text: missing

text: China:Guangxi province

text: missing

text: Phyllostachys edulis

text: biological replicate 1

text: 4℃

characteristic: temp

text: Five leaves and one heart

text: Plant sample from Phyllostachys edulis

text: cold


text: Zhejiang A&F University

text: live

text: Plant

text: missing

text: missing

text: Five leaf and one heart stage

text: missing

characteristic: ecotype

text: China:Guangxi province

text: missing

characteristic: isolate

text: Phyllostachys edulis

text: biological replicate 1

text: Five leaves and one heart

text: Plant sample from Phyllostachys edulis

characteristic: title

text: heat


UV

characteristic: External Id

text: Zhejiang A&F University

text: live

text: Plant

text: missing

text: missing

text: Five leaf and one heart stage

text: missing

text: China:Guangxi province

text: missing

text: Phyllostachys edulis

text: biological replicate 1

characteristic: replicate

text: Five leaves and one heart

characteristic: tissue

text: Plant sample from Phyllostachys edulis

text: uv


CK

text: Zhejiang A&F University

characteristic: INSDC center name

characteristic: INSDC first public

text: live

text: Plant

text: missing

text: missing

text: Five leaf and one heart stage

text: missing

text: China:Guangxi province

text: missing

text: Phyllostachys edulis

text: biological replicate 1

text: Five leaves and one heart

text: Plant sample from Phyllostachys edulis

text: normal

characteristic: treatment


Sa

text: Zhejiang A&F University

characteristic: INSDC last update

text: live

characteristic: INSDC status

text: Plant

characteristic: NCBI submission model

text: missing

text: missing

text: Five leaf and one heart stage

text: missing

text: China:Guangxi province

text: missing

text: Phyllostachys edulis

text: biological replicate 1

text: Five leaves and one heart

text: Plant sample from Phyllostachys edulis

text: salt


Wa

text: Zhejiang A&F University

text: live

text: Plant

characteristic: NCBI submission package

characteristic: SRA accession

text: missing

text: missing

text: Five leaf and one heart stage

text: missing

text: China:Guangxi province

text: missing

text: Phyllostachys edulis

text: biological replicate 1

text: Five leaves and one heart

text: Plant sample from Phyllostachys edulis


DSM 6768

text: Technische Universitaet Muenchen

text: live

text: Microbe, viral or environmental

characteristic: culture-collection

text: Israel

text: Dead Sea

text: Chromohalobacter israelensis

characteristic: organism

text: cell culture

text: DSM 6768

characteristic: strain

text: Microbe sample from Chromohalobacter israelensis

text: type strain of Halomonas israelensis

characteristic: type-material


text: NYU Grossman School of Medicine

characteristic: INSDC secondary accession

text: live

text: MIGS.ba

text: MIGS/MIMS/MIMARKS.human-gut

text: Keywords: GSC:MIxS;MIGS:6.0

characteristic: description

text: Human gut

text: human gut microbiome

text: feces

text: Homo sapiens

characteristic: host

text: TSBA or BHI plates

text: Mediterraneibacter gnavus

text: [Ruminococcus] gnavus isolate strain CC55_001C (RG2)


characteristic: External Id

text: NYU Grossman School of Medicine

text: live

text: MIGS.ba

text: MIGS/MIMS/MIMARKS.human-gut

text: Keywords: GSC:MIxS;MIGS:6.0

text: Human gut

text: human gut microbiome

text: feces

text: Asian

characteristic: ethnicity

text: Homo sapiens

text: autoimmune

text: female

text: TSBA or BHI plates

text: Mediterraneibacter gnavus

text: [Ruminococcus] gnavus isolate S47-18

characteristic: title


text: NYU Grossman School of Medicine

characteristic: INSDC center name

characteristic: INSDC first public

text: live

text: MIGS.ba

text: MIGS/MIMS/MIMARKS.human-gut

text: Keywords: GSC:MIxS;MIGS:6.0

text: Human gut

text: human gut microbiome

text: feces

text: Hispanic White

text: Homo sapiens

text: autoimmune

text: female

text: TSBA or BHI plates

text: Mediterraneibacter gnavus

text: [Ruminococcus] gnavus isolate S107-48


text: NYU Grossman School of Medicine

characteristic: INSDC last update

text: live

text: MIGS.ba

text: MIGS/MIMS/MIMARKS.human-gut

text: Keywords: GSC:MIxS;MIGS:6.0

text: Human gut

text: human gut microbiome

text: feces

text: Hispanic White

text: Homo sapiens

text: autoimmune

text: female

text: TSBA or BHI plates

text: Mediterraneibacter gnavus

text: [Ruminococcus] gnavus isolate S107-61


text: NYU Grossman School of Medicine

text: live

characteristic: INSDC status

text: MIGS.ba

text: MIGS/MIMS/MIMARKS.human-gut

text: Keywords: GSC:MIxS;MIGS:6.0

text: Human gut

text: human gut microbiome

text: feces

text: Hispanic White

text: Homo sapiens

text: autoimmune

text: female

text: TSBA or BHI plates

text: Mediterraneibacter gnavus

text: [Ruminococcus] gnavus isolate S107-86


text: Hubei Academy of Agricultural Sciences

text: live

text: Plant

characteristic: NCBI submission model

text: three fully-expanded leaves stage

text: not collected

characteristic: ecotype

text: not collected

text: not collected

characteristic: isolate

text: Triticum aestivum

text: leaves

characteristic: tissue

text: surface-submerge (SS: keeping the water level at surface soil level 1 cm)

characteristic: treatment


text: Hubei Academy of Agricultural Sciences

text: live

text: Plant

characteristic: NCBI submission package

characteristic: SRA accession

text: three fully-expanded leaves stage

text: not collected

text: not collected

text: not collected

text: Triticum aestivum

characteristic: organism

text: leaves

text: half-submerge (HS: keeping the water level at half of plant height)


text: Hubei Academy of Agricultural Sciences

characteristic: INSDC secondary accession

text: live

text: Plant

text: three fully-expanded leaves stage

text: not collected

text: not collected

text: not collected

text: Triticum aestivum

text: leaves

text: full-submerge (FS: keeping the plants were full submerged)


text: Hubei Academy of Agricultural Sciences

text: live

text: Plant

text: three fully-expanded leaves stage

text: not collected

text: not collected

text: not collected

text: Triticum aestivum

text: leaves

text: Normal watered


CBS 183.55

text: Institute of Microbiology, Chinese Academy of Sciences

text: live

text: Microbe, viral or environmental

text: Karin Sinnema

text: E. Muller

text: France: Menise sur Tholon

text: Rumex alpestris

characteristic: host

text: Didymella exigua

text: whole organism

text: CBS 183.55

characteristic: strain

text: Microbe sample from Didymella exigua

text: culture from neotype of Didymosphaeria exigua

characteristic: type-material


CBS 923.96

characteristic: External Id

text: live

text: Microbe, viral or environmental

text: Karin Sinnema

text: G. Verkley

text: Germany: Bad Bentheim, Bentheimer relictwald, near Kuhrort

text: Carpinus betulus

text: Pezicula carpinea

text: whole organism

text: CBS 923.96

text: Microbe sample from Pezicula carpinea

characteristic: title

text: culture from epitype of Peziza carpinea


text: Zhejiang A&F University

characteristic: INSDC center name

characteristic: INSDC first public

text: live

text: Pathogen.cl

text: Zhejiang A&F University

text: China: Hangzhou

text: Duck

text: hydrohymenitis

text: China: Zhejiang

text: 30.2565 N 119.7282 E

text: Enterobacter chuandaensis

text: Enterobacter chuandaensis E20191216


text: MR

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC last update

text: live

characteristic: INSDC status

text: Human

characteristic: RIN

text: TruSeq Stranded mRNA (non-FFPE compatible)

characteristic: age

characteristic: batch

text: Parekh Lab, Icahn School of Medicine at Mount Sinai

text: multiple myeloma

characteristic: disease

text: II

text: CD138+ cells from patient ID STORM_001 who participated in the STORM study and recieved selinexor + dexamethasone

text: Homo sapiens

text: female

characteristic: sex

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + dexamethasone


text: MR

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

characteristic: SRA accession

text: multiple myeloma

text: II

text: CD138+ cells from patient ID STORM_002 who participated in the STORM study and recieved selinexor + dexamethasone

characteristic: isolate

text: Homo sapiens

text: female

text: bone marrow

characteristic: tissue

text: Human sample from Homo sapiens

text: selinexor + dexamethasone

characteristic: treatment


text: PR

characteristic: External Id

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC secondary accession

text: live

text: Human

text: multiple myeloma

text: I

text: CD138+ cells from patient ID STORM_003 who participated in the STORM study and recieved selinexor + dexamethasone

text: Homo sapiens

characteristic: organism

text: female

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + dexamethasone


text: SD

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC center name

characteristic: INSDC first public

text: live

text: Human

text: multiple myeloma

text: II

text: CD138+ cells from patient ID STORM_004 who participated in the STORM study and recieved selinexor + dexamethasone

text: Homo sapiens

text: female

text: bone marrow

text: Human sample from Homo sapiens

characteristic: title

text: selinexor + dexamethasone


text: SD

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC last update

text: live

characteristic: INSDC status

text: Human

characteristic: RIN

text: multiple myeloma

text: II

text: CD138+ cells from patient ID STORM_005 who participated in the STORM study and recieved selinexor + dexamethasone

text: Homo sapiens

text: male

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + dexamethasone


text: SD

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

characteristic: age

characteristic: batch

text: multiple myeloma

characteristic: disease

text: II

text: CD138+ cells from patient ID STORM_006 who participated in the STORM study and recieved selinexor + dexamethasone

text: Homo sapiens

text: male

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + dexamethasone


text: MR

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

text: multiple myeloma

text: III

text: CD138+ cells from patient ID STORM_007 who participated in the STORM study and recieved selinexor + dexamethasone

text: Homo sapiens

text: female

characteristic: sex

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + dexamethasone


text: SD

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

characteristic: SRA accession

text: multiple myeloma

text: II

text: CD138+ cells from patient ID STORM_008 who participated in the STORM study and recieved selinexor + dexamethasone

characteristic: isolate

text: Homo sapiens

text: male

text: bone marrow

characteristic: tissue

text: Human sample from Homo sapiens

text: selinexor + dexamethasone


text: SD

characteristic: External Id

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC secondary accession

text: live

text: Human

text: multiple myeloma

text: III

text: CD138+ cells from patient ID STORM_009 who participated in the STORM study and recieved selinexor + dexamethasone

text: Homo sapiens

text: male

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + dexamethasone

characteristic: treatment


text: VGPR

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC center name

characteristic: INSDC first public

text: live

text: Human

text: multiple myeloma

text: II

text: CD138+ cells from patient ID STORM_010 who participated in the STORM study and recieved selinexor + dexamethasone

text: Homo sapiens

characteristic: organism

text: female

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + dexamethasone


text: SD

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC last update

text: live

characteristic: INSDC status

text: Human

text: multiple myeloma

text: III

text: CD138+ cells from patient ID STORM_011 who participated in the STORM study and recieved selinexor + dexamethasone

text: Homo sapiens

text: male

text: bone marrow

text: Human sample from Homo sapiens

characteristic: title

text: selinexor + dexamethasone


text: PR

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

characteristic: RIN

characteristic: age

characteristic: batch

text: multiple myeloma

text: II

text: CD138+ cells from patient ID STORM_012 who participated in the STORM study and recieved selinexor + dexamethasone

text: Homo sapiens

text: female

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + dexamethasone


text: SD

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

text: multiple myeloma

characteristic: disease

text: II

text: CD138+ cells from patient ID STORM_013 who participated in the STORM study and recieved selinexor + dexamethasone

text: Homo sapiens

text: male

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + dexamethasone


text: SD

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

characteristic: SRA accession

text: multiple myeloma

text: III

text: CD138+ cells from patient ID STORM_014 who participated in the STORM study and recieved selinexor + dexamethasone

characteristic: isolate

text: Homo sapiens

text: female

characteristic: sex

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + dexamethasone


text: SD

characteristic: External Id

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC secondary accession

text: live

text: Human

text: multiple myeloma

text: II

text: CD138+ cells from patient ID STORM_015 who participated in the STORM study and recieved selinexor + dexamethasone

text: Homo sapiens

text: female

text: bone marrow

characteristic: tissue

text: Human sample from Homo sapiens

text: selinexor + dexamethasone


text: PR

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC center name

characteristic: INSDC first public

text: live

text: Human

text: TruSeq Stranded mRNA (non-FFPE compatible)

text: multiple myeloma

text: II

text: CD138+ cells from patient ID STORM_016 who participated in the STORM study and recieved selinexor + dexamethasone

text: Homo sapiens

text: male

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + dexamethasone

characteristic: treatment


text: PD

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC last update

text: live

characteristic: INSDC status

text: Human

text: Parekh Lab, Icahn School of Medicine at Mount Sinai

text: multiple myeloma

text: II

text: CD138+ cells from patient ID STORM_017 who participated in the STORM study and recieved selinexor + dexamethasone

text: Homo sapiens

characteristic: organism

text: male

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + dexamethasone


text: PR

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

characteristic: RIN

characteristic: age

text: multiple myeloma

text: II

text: CD138+ cells from patient ID STORM_018 who participated in the STORM study and recieved selinexor + dexamethasone

text: Homo sapiens

text: female

text: bone marrow

text: Human sample from Homo sapiens

characteristic: title

text: selinexor + dexamethasone


text: sCR

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

characteristic: batch

text: multiple myeloma

text: II

text: CD138+ cells from patient ID STORM_019 who participated in the STORM study and recieved selinexor + dexamethasone

text: Homo sapiens

text: female

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + dexamethasone


text: PR

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

characteristic: SRA accession

text: multiple myeloma

characteristic: disease

text: II

text: CD138+ cells from patient ID STORM_020 who participated in the STORM study and recieved selinexor + dexamethasone

characteristic: isolate

text: Homo sapiens

text: female

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + dexamethasone


text: SD

characteristic: External Id

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC secondary accession

text: live

text: Human

text: multiple myeloma

text: III

text: CD138+ cells from patient ID STORM_021 who participated in the STORM study and recieved selinexor + dexamethasone

text: Homo sapiens

text: female

characteristic: sex

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + dexamethasone


text: MR

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC center name

characteristic: INSDC first public

text: live

text: Human

text: multiple myeloma

text: II

text: CD138+ cells from patient ID STORM_022 who participated in the STORM study and recieved selinexor + dexamethasone

text: Homo sapiens

text: male

text: bone marrow

characteristic: tissue

text: Human sample from Homo sapiens

text: selinexor + dexamethasone


text: SD

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC last update

text: live

characteristic: INSDC status

text: Human

text: multiple myeloma

text: II

text: CD138+ cells from patient ID STORM_023 who participated in the STORM study and recieved selinexor + dexamethasone

text: Homo sapiens

text: female

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + dexamethasone

characteristic: treatment


text: SD

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

characteristic: RIN

characteristic: age

text: multiple myeloma

text: II

text: CD138+ cells from patient ID STORM_024 who participated in the STORM study and recieved selinexor + dexamethasone

text: Homo sapiens

characteristic: organism

text: male

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + dexamethasone


text: SD

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

text: multiple myeloma

text: I

text: CD138+ cells from patient ID STORM_025 who participated in the STORM study and recieved selinexor + dexamethasone

text: Homo sapiens

text: male

text: bone marrow

text: Human sample from Homo sapiens

characteristic: title

text: selinexor + dexamethasone


text: SD

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

characteristic: SRA accession

characteristic: batch

text: multiple myeloma

characteristic: disease

text: I

text: CD138+ cells from patient ID STORM_026 who participated in the STORM study and recieved selinexor + dexamethasone

text: Homo sapiens

text: male

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + dexamethasone


text: SD

characteristic: External Id

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC secondary accession

text: live

text: Human

text: multiple myeloma

text: I

text: CD138+ cells from patient ID STORM_027 who participated in the STORM study and recieved selinexor + dexamethasone

characteristic: isolate

text: Homo sapiens

text: male

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + dexamethasone


text: MR

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC center name

characteristic: INSDC first public

text: live

text: Human

text: multiple myeloma

text: III

text: CD138+ cells from patient ID STORM_028 who participated in the STORM study and recieved selinexor + dexamethasone

text: Homo sapiens

text: female

characteristic: sex

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + dexamethasone


text: PR

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC last update

text: live

characteristic: INSDC status

text: Human

text: multiple myeloma

text: II

text: CD138+ cells from patient ID STORM_029 who participated in the STORM study and recieved selinexor + dexamethasone

text: Homo sapiens

text: female

text: bone marrow

characteristic: tissue

text: Human sample from Homo sapiens

text: selinexor + dexamethasone


text: MR

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

characteristic: RIN

characteristic: age

text: multiple myeloma

text: II

text: CD138+ cells from patient ID STORM_030 who participated in the STORM study and recieved selinexor + dexamethasone

text: Homo sapiens

text: female

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + dexamethasone

characteristic: treatment


text: SD

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

text: TruSeq Stranded mRNA (non-FFPE compatible)

text: multiple myeloma

text: II

text: CD138+ cells from patient ID STORM_031 who participated in the STORM study and recieved selinexor + dexamethasone

text: Homo sapiens

characteristic: organism

text: male

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + dexamethasone


text: PD

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

characteristic: SRA accession

characteristic: batch

text: Parekh Lab, Icahn School of Medicine at Mount Sinai

text: multiple myeloma

text: II

text: CD138+ cells from patient ID STORM_032 who participated in the STORM study and recieved selinexor + dexamethasone

text: Homo sapiens

text: female

text: bone marrow

text: Human sample from Homo sapiens

characteristic: title

text: selinexor + dexamethasone


text: MR

characteristic: External Id

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC secondary accession

text: live

text: Human

text: multiple myeloma

characteristic: disease

text: II

text: CD138+ cells from patient ID STORM_033 who participated in the STORM study and recieved selinexor + dexamethasone

text: Homo sapiens

text: female

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + dexamethasone


text: MR

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC center name

characteristic: INSDC first public

text: live

text: Human

text: multiple myeloma

text: I

text: CD138+ cells from patient ID STORM_034 who participated in the STORM study and recieved selinexor + dexamethasone

characteristic: isolate

text: Homo sapiens

text: female

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + dexamethasone


text: MR

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC last update

text: live

characteristic: INSDC status

text: Human

text: multiple myeloma

text: II

text: CD138+ cells from patient ID STORM_035 who participated in the STORM study and recieved selinexor + dexamethasone

text: Homo sapiens

text: male

characteristic: sex

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + dexamethasone


text: SD

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

characteristic: RIN

characteristic: age

text: multiple myeloma

text: III

text: CD138+ cells from patient ID STORM_036 who participated in the STORM study and recieved selinexor + dexamethasone

text: Homo sapiens

text: male

text: bone marrow

characteristic: tissue

text: Human sample from Homo sapiens

text: selinexor + dexamethasone


text: SD

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

text: multiple myeloma

text: II

text: CD138+ cells from patient ID STORM_037 who participated in the STORM study and recieved selinexor + dexamethasone

text: Homo sapiens

text: male

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + dexamethasone

characteristic: treatment


text: SD

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

characteristic: SRA accession

characteristic: batch

text: multiple myeloma

text: III

text: CD138+ cells from patient ID STORM_038 who participated in the STORM study and recieved selinexor + dexamethasone

text: Homo sapiens

characteristic: organism

text: male

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + dexamethasone


text: VGPR

characteristic: External Id

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC secondary accession

text: live

text: Human

text: multiple myeloma

text: II

text: CD138+ cells from patient ID STORM_039 who participated in the STORM study and recieved selinexor + dexamethasone

text: Homo sapiens

text: male

text: bone marrow

text: Human sample from Homo sapiens

characteristic: title

text: selinexor + dexamethasone


text: PR

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC center name

characteristic: INSDC first public

text: live

text: Human

text: multiple myeloma

characteristic: disease

text: II

text: CD138+ cells from patient ID STORM_040 who participated in the STORM study and recieved selinexor + dexamethasone

text: Homo sapiens

text: male

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + dexamethasone


text: PR

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC last update

text: live

characteristic: INSDC status

text: Human

text: multiple myeloma

text: I

text: CD138+ cells from patient ID STORM_041 who participated in the STORM study and recieved selinexor + dexamethasone

characteristic: isolate

text: Homo sapiens

text: female

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + dexamethasone


text: SD

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

characteristic: RIN

characteristic: age

text: multiple myeloma

text: II

text: CD138+ cells from patient ID STORM_042 who participated in the STORM study and recieved selinexor + dexamethasone

text: Homo sapiens

text: male

characteristic: sex

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + dexamethasone


text: PR

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

text: multiple myeloma

text: II

text: CD138+ cells from patient ID STORM_043 who participated in the STORM study and recieved selinexor + dexamethasone

text: Homo sapiens

text: female

text: bone marrow

characteristic: tissue

text: Human sample from Homo sapiens

text: selinexor + dexamethasone


text: SD

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

characteristic: SRA accession

characteristic: batch

text: multiple myeloma

text: I

text: CD138+ cells from patient ID STORM_044 who participated in the STORM study and recieved selinexor + dexamethasone

text: Homo sapiens

text: male

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + dexamethasone

characteristic: treatment


text: PD

characteristic: External Id

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC secondary accession

text: live

text: Human

text: multiple myeloma

text: II

text: CD138+ cells from patient ID STORM_045 who participated in the STORM study and recieved selinexor + dexamethasone

text: Homo sapiens

characteristic: organism

text: female

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + dexamethasone


text: SD

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC center name

characteristic: INSDC first public

text: live

text: Human

text: TruSeq Stranded mRNA (non-FFPE compatible)

text: multiple myeloma

text: II

text: CD138+ cells from patient ID STORM_046 who participated in the STORM study and recieved selinexor + dexamethasone

text: Homo sapiens

text: female

text: bone marrow

text: Human sample from Homo sapiens

characteristic: title

text: selinexor + dexamethasone


text: PR

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC last update

text: live

characteristic: INSDC status

text: Human

text: Parekh Lab, Icahn School of Medicine at Mount Sinai

text: multiple myeloma

characteristic: disease

text: II

text: CD138+ cells from patient ID STORM_047 who participated in the STORM study and recieved selinexor + dexamethasone

text: Homo sapiens

text: female

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + dexamethasone


text: SD

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

characteristic: RIN

characteristic: age

text: multiple myeloma

text: II

text: CD138+ cells from patient ID STORM_048 who participated in the STORM study and recieved selinexor + dexamethasone

characteristic: isolate

text: Homo sapiens

text: female

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + dexamethasone


text: MR

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

text: multiple myeloma

text: II

text: CD138+ cells from patient ID STORM_049 who participated in the STORM study and recieved selinexor + dexamethasone

text: Homo sapiens

text: male

characteristic: sex

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + dexamethasone


text: MR

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

characteristic: SRA accession

characteristic: batch

text: multiple myeloma

text: II

text: CD138+ cells from patient ID STORM_050 who participated in the STORM study and recieved selinexor + dexamethasone

text: Homo sapiens

text: male

text: bone marrow

characteristic: tissue

text: Human sample from Homo sapiens

text: selinexor + dexamethasone


text: SD

characteristic: External Id

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC secondary accession

text: live

text: Human

text: multiple myeloma

text: III

text: CD138+ cells from patient ID STORM_051 who participated in the STORM study and recieved selinexor + dexamethasone

text: Homo sapiens

text: female

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + dexamethasone

characteristic: treatment


text: SD

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC center name

characteristic: INSDC first public

text: live

text: Human

text: multiple myeloma

text: II

text: CD138+ cells from patient ID STORM_052 who participated in the STORM study and recieved selinexor + dexamethasone

text: Homo sapiens

characteristic: organism

text: male

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + dexamethasone


text: VGPR

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC last update

text: live

characteristic: INSDC status

text: Human

text: multiple myeloma

text: II

text: CD138+ cells from patient ID STORM_053 who participated in the STORM study and recieved selinexor + dexamethasone

text: Homo sapiens

text: male

text: bone marrow

text: Human sample from Homo sapiens

characteristic: title

text: selinexor + dexamethasone


text: VGPR

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

characteristic: RIN

characteristic: age

text: multiple myeloma

characteristic: disease

text: II

text: CD138+ cells from patient ID STORM_054 who participated in the STORM study and recieved selinexor + dexamethasone

text: Homo sapiens

text: male

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + dexamethasone


text: PD

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

text: multiple myeloma

text: III

text: CD138+ cells from patient ID STORM_055 who participated in the STORM study and recieved selinexor + dexamethasone

characteristic: isolate

text: Homo sapiens

text: male

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + dexamethasone


text: PR

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

characteristic: SRA accession

characteristic: batch

text: multiple myeloma

text: I

text: CD138+ cells from patient ID STORM_056 who participated in the STORM study and recieved selinexor + dexamethasone

text: Homo sapiens

text: female

characteristic: sex

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + dexamethasone


text: PD

characteristic: External Id

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC secondary accession

text: live

text: Human

text: multiple myeloma

text: II

text: CD138+ cells from patient ID STORM_057 who participated in the STORM study and recieved selinexor + dexamethasone

text: Homo sapiens

text: male

text: bone marrow

characteristic: tissue

text: Human sample from Homo sapiens

text: selinexor + dexamethasone


text: SD

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC center name

characteristic: INSDC first public

text: live

text: Human

text: multiple myeloma

text: III

text: CD138+ cells from patient ID STORM_058 who participated in the STORM study and recieved selinexor + dexamethasone

text: Homo sapiens

text: male

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + dexamethasone

characteristic: treatment


text: PR

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC last update

text: live

characteristic: INSDC status

text: Human

text: multiple myeloma

text: I

text: CD138+ cells from patient ID STORM_059 who participated in the STORM study and recieved selinexor + dexamethasone

text: Homo sapiens

characteristic: organism

text: male

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + dexamethasone


text: sCR

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

characteristic: RIN

characteristic: age

text: multiple myeloma

text: I

text: CD138+ cells from patient ID STORM_060 who participated in the STORM study and recieved selinexor + dexamethasone

text: Homo sapiens

text: female

text: bone marrow

text: Human sample from Homo sapiens

characteristic: title

text: selinexor + dexamethasone


text: SD

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

text: TruSeq Stranded mRNA (non-FFPE compatible)

text: multiple myeloma

characteristic: disease

text: II

text: CD138+ cells from patient ID STORM_061 who participated in the STORM study and recieved selinexor + dexamethasone

text: Homo sapiens

text: female

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + dexamethasone


text: SD

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

characteristic: SRA accession

characteristic: batch

text: Parekh Lab, Icahn School of Medicine at Mount Sinai

text: multiple myeloma

text: III

text: CD138+ cells from patient ID STORM_062 who participated in the STORM study and recieved selinexor + dexamethasone

characteristic: isolate

text: Homo sapiens

text: female

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + dexamethasone


text: SD

characteristic: External Id

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC secondary accession

text: live

text: Human

text: multiple myeloma

text: II

text: CD138+ cells from patient ID STORM_063 who participated in the STORM study and recieved selinexor + dexamethasone

text: Homo sapiens

text: female

characteristic: sex

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + dexamethasone


text: SD

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC center name

characteristic: INSDC first public

text: live

text: Human

text: multiple myeloma

text: I

text: CD138+ cells from patient ID STORM_064 who participated in the STORM study and recieved selinexor + dexamethasone

text: Homo sapiens

text: male

text: bone marrow

characteristic: tissue

text: Human sample from Homo sapiens

text: selinexor + dexamethasone


text: VGPR

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC last update

text: live

characteristic: INSDC status

text: Human

text: Smart-Seq V4 Ultra Low Input Nextera XT

text: multiple myeloma

text: I

text: CD138+ cells from patient ID BOSTON_001 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

text: female

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone

characteristic: treatment


text: VGPR

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

characteristic: RIN

text: Smart-Seq V4 Ultra Low Input Nextera XT

characteristic: age

text: multiple myeloma

text: I

text: CD138+ cells from patient ID BOSTON_002 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

characteristic: organism

text: male

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone


text: VGPR

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

text: Smart-Seq V4 Ultra Low Input Nextera XT

text: multiple myeloma

text: I

text: CD138+ cells from patient ID BOSTON_003 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

text: male

text: bone marrow

text: Human sample from Homo sapiens

characteristic: title

text: selinexor + bortezomib + dexamethasone


text: PR

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

text: Smart-Seq V4 Ultra Low Input Nextera XT

characteristic: SRA accession

characteristic: batch

text: multiple myeloma

characteristic: disease

text: I

text: CD138+ cells from patient ID BOSTON_004 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

text: female

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone


text: CR

characteristic: External Id

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC secondary accession

text: live

text: Human

text: Smart-Seq V4 Ultra Low Input Nextera XT

text: multiple myeloma

text: I

text: CD138+ cells from patient ID BOSTON_005 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

characteristic: isolate

text: Homo sapiens

text: male

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone


text: PD

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC center name

characteristic: INSDC first public

text: live

text: Human

text: Smart-Seq V4 Ultra Low Input Nextera XT

text: multiple myeloma

text: II

text: CD138+ cells from patient ID BOSTON_006 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

text: male

characteristic: sex

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone


text: CR

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC last update

text: live

characteristic: INSDC status

text: Human

text: Smart-Seq V4 Ultra Low Input Nextera XT

text: multiple myeloma

text: I

text: CD138+ cells from patient ID BOSTON_007 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

text: male

text: bone marrow

characteristic: tissue

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone


text: MR

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

characteristic: RIN

characteristic: age

text: multiple myeloma

text: I

text: CD138+ cells from patient ID BOSTON_008 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

text: female

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone

characteristic: treatment


text: VGPR

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

text: Smart-Seq V4 Ultra Low Input Nextera XT

text: multiple myeloma

text: II

text: CD138+ cells from patient ID BOSTON_009 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

characteristic: organism

text: male

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone


text: SD

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

characteristic: SRA accession

characteristic: batch

text: multiple myeloma

text: I

text: CD138+ cells from patient ID BOSTON_010 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

text: male

text: bone marrow

text: Human sample from Homo sapiens

characteristic: title

text: selinexor + bortezomib + dexamethasone


text: PR

characteristic: External Id

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC secondary accession

text: live

text: Human

text: Smart-Seq V4 Ultra Low Input Nextera XT

text: multiple myeloma

characteristic: disease

text: III

text: CD138+ cells from patient ID BOSTON_011 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

text: male

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone


text: PD

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC center name

characteristic: INSDC first public

text: live

text: Human

text: TruSeq Stranded mRNA (non-FFPE compatible)

text: multiple myeloma

text: II

text: CD138+ cells from patient ID BOSTON_012 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

characteristic: isolate

text: Homo sapiens

text: female

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone


text: VGPR

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC last update

text: live

characteristic: INSDC status

text: Human

text: Parekh Lab, Icahn School of Medicine at Mount Sinai

text: multiple myeloma

text: II

text: CD138+ cells from patient ID BOSTON_013 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

text: male

characteristic: sex

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone


text: PD

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

characteristic: RIN

text: Smart-Seq V4 Ultra Low Input Nextera XT

characteristic: age

text: multiple myeloma

text: I

text: CD138+ cells from patient ID BOSTON_014 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

text: male

text: bone marrow

characteristic: tissue

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone


text: sCR

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

text: Smart-Seq V4 Ultra Low Input Nextera XT

text: multiple myeloma

text: I

text: CD138+ cells from patient ID BOSTON_015 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

text: male

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone

characteristic: treatment


text: PR

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

text: Smart-Seq V4 Ultra Low Input Nextera XT

characteristic: SRA accession

characteristic: batch

text: multiple myeloma

text: I

text: CD138+ cells from patient ID BOSTON_016 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

characteristic: organism

text: female

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone


text: PR

characteristic: External Id

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC secondary accession

text: live

text: Human

text: multiple myeloma

text: II

text: CD138+ cells from patient ID BOSTON_017 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

text: male

text: bone marrow

text: Human sample from Homo sapiens

characteristic: title

text: selinexor + bortezomib + dexamethasone


text: MR

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC center name

characteristic: INSDC first public

text: live

text: Human

text: multiple myeloma

characteristic: disease

text: I

text: CD138+ cells from patient ID BOSTON_018 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

text: male

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone


text: SD

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC last update

text: live

characteristic: INSDC status

text: Human

text: multiple myeloma

text: II

text: CD138+ cells from patient ID BOSTON_019 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

characteristic: isolate

text: Homo sapiens

text: female

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone


text: VGPR

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

characteristic: RIN

characteristic: age

text: multiple myeloma

text: I

text: CD138+ cells from patient ID BOSTON_020 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

text: male

characteristic: sex

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone


text: VGPR

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

text: multiple myeloma

text: III

text: CD138+ cells from patient ID BOSTON_021 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

text: male

text: bone marrow

characteristic: tissue

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone


text: MR

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

text: Smart-Seq V4 Ultra Low Input Nextera XT

characteristic: SRA accession

characteristic: batch

text: multiple myeloma

text: I

text: CD138+ cells from patient ID BOSTON_022 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

text: male

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone

characteristic: treatment


text: PR

characteristic: External Id

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC secondary accession

text: live

text: Human

text: Smart-Seq V4 Ultra Low Input Nextera XT

text: multiple myeloma

text: I

text: CD138+ cells from patient ID BOSTON_023 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

characteristic: organism

text: male

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone


text: PR

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC center name

characteristic: INSDC first public

text: live

text: Human

text: multiple myeloma

text: II

text: CD138+ cells from patient ID BOSTON_024 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

text: female

text: bone marrow

text: Human sample from Homo sapiens

characteristic: title

text: selinexor + bortezomib + dexamethasone


text: PR

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC last update

text: live

characteristic: INSDC status

text: Human

text: multiple myeloma

characteristic: disease

text: II

text: CD138+ cells from patient ID BOSTON_025 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

text: female

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone


text: SD

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

characteristic: RIN

characteristic: age

text: multiple myeloma

text: III

text: CD138+ cells from patient ID BOSTON_026 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

characteristic: isolate

text: Homo sapiens

text: female

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone


text: VGPR

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

text: TruSeq Stranded mRNA (non-FFPE compatible)

text: multiple myeloma

text: II

text: CD138+ cells from patient ID BOSTON_027 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

text: male

characteristic: sex

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone


text: SD

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

characteristic: SRA accession

characteristic: batch

text: Parekh Lab, Icahn School of Medicine at Mount Sinai

text: multiple myeloma

text: I

text: CD138+ cells from patient ID BOSTON_028 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

text: male

text: bone marrow

characteristic: tissue

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone


text: VGPR

characteristic: External Id

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC secondary accession

text: live

text: Human

text: Smart-Seq V4 Ultra Low Input Nextera XT

text: multiple myeloma

text: II

text: CD138+ cells from patient ID BOSTON_029 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

text: male

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone

characteristic: treatment


text: PR

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC center name

characteristic: INSDC first public

text: live

text: Human

text: multiple myeloma

text: III

text: CD138+ cells from patient ID BOSTON_030 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

characteristic: organism

text: female

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone


text: SD

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC last update

text: live

characteristic: INSDC status

text: Human

text: multiple myeloma

text: II

text: CD138+ cells from patient ID BOSTON_031 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

text: male

text: bone marrow

text: Human sample from Homo sapiens

characteristic: title

text: selinexor + bortezomib + dexamethasone


text: PD

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

characteristic: RIN

characteristic: age

text: multiple myeloma

characteristic: disease

text: III

text: CD138+ cells from patient ID BOSTON_032 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

text: female

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone


text: VGPR

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

text: multiple myeloma

text: I

text: CD138+ cells from patient ID BOSTON_033 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

characteristic: isolate

text: Homo sapiens

text: male

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone


text: SD

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

characteristic: SRA accession

characteristic: batch

text: multiple myeloma

text: II

text: CD138+ cells from patient ID BOSTON_034 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

text: male

characteristic: sex

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone


text: PR

characteristic: External Id

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC secondary accession

text: live

text: Human

text: multiple myeloma

text: I

text: CD138+ cells from patient ID BOSTON_035 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

text: female

text: bone marrow

characteristic: tissue

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone


text: PR

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC center name

characteristic: INSDC first public

text: live

text: Human

text: multiple myeloma

text: I

text: CD138+ cells from patient ID BOSTON_036 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

text: male

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone

characteristic: treatment


text: VGPR

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC last update

text: live

characteristic: INSDC status

text: Human

text: multiple myeloma

text: I

text: CD138+ cells from patient ID BOSTON_037 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

characteristic: organism

text: female

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone


text: PR

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

characteristic: RIN

characteristic: age

text: multiple myeloma

text: III

text: CD138+ cells from patient ID BOSTON_038 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

text: male

text: bone marrow

text: Human sample from Homo sapiens

characteristic: title

text: selinexor + bortezomib + dexamethasone


text: VGPR

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

text: multiple myeloma

characteristic: disease

text: I

text: CD138+ cells from patient ID BOSTON_039 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

text: female

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone


text: VGPR

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

text: Smart-Seq V4 Ultra Low Input Nextera XT

characteristic: SRA accession

characteristic: batch

text: multiple myeloma

text: I

text: CD138+ cells from patient ID BOSTON_040 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

characteristic: isolate

text: Homo sapiens

text: male

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone


text: VGPR

characteristic: External Id

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC secondary accession

text: live

text: Human

text: multiple myeloma

text: I

text: CD138+ cells from patient ID BOSTON_041 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

text: female

characteristic: sex

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone


text: sCR

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC center name

characteristic: INSDC first public

text: live

text: Human

text: Smart-Seq V4 Ultra Low Input Nextera XT

text: multiple myeloma

text: I

text: CD138+ cells from patient ID BOSTON_042 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

text: male

text: bone marrow

characteristic: tissue

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone


text: VGPR

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC last update

text: live

characteristic: INSDC status

text: Human

text: TruSeq Stranded mRNA (non-FFPE compatible)

text: multiple myeloma

text: III

text: CD138+ cells from patient ID BOSTON_043 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

text: male

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone

characteristic: treatment


text: VGPR

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

characteristic: RIN

characteristic: age

text: Parekh Lab, Icahn School of Medicine at Mount Sinai

text: multiple myeloma

text: III

text: CD138+ cells from patient ID BOSTON_044 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

characteristic: organism

text: male

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone


text: VGPR

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

text: Smart-Seq V4 Ultra Low Input Nextera XT

text: multiple myeloma

text: II

text: CD138+ cells from patient ID BOSTON_045 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

text: male

text: bone marrow

text: Human sample from Homo sapiens

characteristic: title

text: selinexor + bortezomib + dexamethasone


text: MR

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

characteristic: SRA accession

characteristic: batch

text: multiple myeloma

characteristic: disease

text: II

text: CD138+ cells from patient ID BOSTON_046 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

text: female

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone


text: SD

characteristic: External Id

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC secondary accession

text: live

text: Human

text: multiple myeloma

text: II

text: CD138+ cells from patient ID BOSTON_047 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

characteristic: isolate

text: Homo sapiens

text: female

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone


text: CR

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC center name

characteristic: INSDC first public

text: live

text: Human

text: multiple myeloma

text: I

text: CD138+ cells from patient ID BOSTON_048 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

text: female

characteristic: sex

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone


text: PR

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC last update

text: live

characteristic: INSDC status

text: Human

text: multiple myeloma

text: I

text: CD138+ cells from patient ID BOSTON_049 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

text: female

text: bone marrow

characteristic: tissue

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone


text: MR

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

characteristic: RIN

characteristic: age

text: multiple myeloma

text: I

text: CD138+ cells from patient ID BOSTON_050 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

text: female

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone

characteristic: treatment


text: PR

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

text: multiple myeloma

text: II

text: CD138+ cells from patient ID BOSTON_051 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

characteristic: organism

text: female

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone


text: SD

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

text: Smart-Seq V4 Ultra Low Input Nextera XT

characteristic: SRA accession

characteristic: batch

text: multiple myeloma

text: II

text: CD138+ cells from patient ID BOSTON_052 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

text: female

text: bone marrow

text: Human sample from Homo sapiens

characteristic: title

text: selinexor + bortezomib + dexamethasone


text: MR

characteristic: External Id

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC secondary accession

text: live

text: Human

text: multiple myeloma

characteristic: disease

text: I

text: CD138+ cells from patient ID BOSTON_053 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

text: male

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone


text: PR

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC center name

characteristic: INSDC first public

text: live

text: Human

text: Smart-Seq V4 Ultra Low Input Nextera XT

text: multiple myeloma

text: III

text: CD138+ cells from patient ID BOSTON_054 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

characteristic: isolate

text: Homo sapiens

text: female

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone


text: PR

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC last update

text: live

characteristic: INSDC status

text: Human

text: multiple myeloma

text: II

text: CD138+ cells from patient ID BOSTON_055 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

text: female

characteristic: sex

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone


text: VGPR

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

characteristic: RIN

characteristic: age

text: multiple myeloma

text: I

text: CD138+ cells from patient ID BOSTON_056 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

text: female

text: bone marrow

characteristic: tissue

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone


text: SD

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

text: Smart-Seq V4 Ultra Low Input Nextera XT

text: multiple myeloma

text: I

text: CD138+ cells from patient ID BOSTON_057 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

text: female

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone

characteristic: treatment


text: PR

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

text: Smart-Seq V4 Ultra Low Input Nextera XT

characteristic: SRA accession

characteristic: batch

text: multiple myeloma

text: I

text: CD138+ cells from patient ID BOSTON_058 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

characteristic: organism

text: female

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone


text: VGPR

characteristic: External Id

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC secondary accession

text: live

text: Human

text: TruSeq Stranded mRNA (non-FFPE compatible)

text: multiple myeloma

text: II

text: CD138+ cells from patient ID BOSTON_059 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

text: female

text: bone marrow

text: Human sample from Homo sapiens

characteristic: title

text: selinexor + bortezomib + dexamethasone


text: MR

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC center name

characteristic: INSDC first public

text: live

text: Human

text: Smart-Seq V4 Ultra Low Input Nextera XT

text: Parekh Lab, Icahn School of Medicine at Mount Sinai

text: multiple myeloma

characteristic: disease

text: I

text: CD138+ cells from patient ID BOSTON_060 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

text: male

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone


text: PR

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC last update

text: live

characteristic: INSDC status

text: Human

text: Smart-Seq V4 Ultra Low Input Nextera XT

text: multiple myeloma

text: I

text: CD138+ cells from patient ID BOSTON_061 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

characteristic: isolate

text: Homo sapiens

text: male

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone


text: VGPR

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

characteristic: RIN

characteristic: age

text: multiple myeloma

text: I

text: CD138+ cells from patient ID BOSTON_062 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

text: male

characteristic: sex

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone


text: VGPR

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

text: Smart-Seq V4 Ultra Low Input Nextera XT

text: multiple myeloma

text: II

text: CD138+ cells from patient ID BOSTON_063 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

text: male

text: bone marrow

characteristic: tissue

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone


text: PR

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

characteristic: SRA accession

characteristic: batch

text: multiple myeloma

text: II

text: CD138+ cells from patient ID BOSTON_064 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

text: female

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone

characteristic: treatment


text: SD

characteristic: External Id

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC secondary accession

text: live

text: Human

text: Smart-Seq V4 Ultra Low Input Nextera XT

text: multiple myeloma

text: II

text: CD138+ cells from patient ID BOSTON_065 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

characteristic: organism

text: male

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone


text: SD

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC center name

characteristic: INSDC first public

text: live

text: Human

text: Smart-Seq V4 Ultra Low Input Nextera XT

text: multiple myeloma

text: III

text: CD138+ cells from patient ID BOSTON_066 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

text: male

text: bone marrow

text: Human sample from Homo sapiens

characteristic: title

text: selinexor + bortezomib + dexamethasone


text: sCR

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC last update

text: live

characteristic: INSDC status

text: Human

text: multiple myeloma

characteristic: disease

text: II

text: CD138+ cells from patient ID BOSTON_067 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

text: female

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone


text: SD

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

characteristic: RIN

characteristic: age

text: multiple myeloma

text: III

text: CD138+ cells from patient ID BOSTON_068 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

characteristic: isolate

text: Homo sapiens

text: female

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone


text: CR

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

text: Smart-Seq V4 Ultra Low Input Nextera XT

text: multiple myeloma

text: III

text: CD138+ cells from patient ID BOSTON_069 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

text: female

characteristic: sex

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone


text: PR

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

text: Smart-Seq V4 Ultra Low Input Nextera XT

characteristic: SRA accession

characteristic: batch

text: multiple myeloma

text: I

text: CD138+ cells from patient ID BOSTON_070 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

text: male

text: bone marrow

characteristic: tissue

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone


text: PR

characteristic: External Id

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC secondary accession

text: live

text: Human

text: multiple myeloma

text: III

text: CD138+ cells from patient ID BOSTON_071 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

text: male

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone

characteristic: treatment


text: VGPR

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC center name

characteristic: INSDC first public

text: live

text: Human

text: Smart-Seq V4 Ultra Low Input Nextera XT

text: multiple myeloma

text: I

text: CD138+ cells from patient ID BOSTON_072 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

characteristic: organism

text: female

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone


text: PR

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC last update

text: live

characteristic: INSDC status

text: Human

text: Smart-Seq V4 Ultra Low Input Nextera XT

text: multiple myeloma

text: II

text: CD138+ cells from patient ID BOSTON_073 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

text: male

text: bone marrow

text: Human sample from Homo sapiens

characteristic: title

text: selinexor + bortezomib + dexamethasone


text: SD

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

characteristic: RIN

text: TruSeq Stranded mRNA (non-FFPE compatible)

characteristic: age

text: multiple myeloma

characteristic: disease

text: I

text: CD138+ cells from patient ID BOSTON_074 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

text: male

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone


text: PR

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

text: Parekh Lab, Icahn School of Medicine at Mount Sinai

text: multiple myeloma

text: I

text: CD138+ cells from patient ID BOSTON_075 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

characteristic: isolate

text: Homo sapiens

text: male

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone


text: PR

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

text: Smart-Seq V4 Ultra Low Input Nextera XT

characteristic: SRA accession

characteristic: batch

text: multiple myeloma

text: II

text: CD138+ cells from patient ID BOSTON_076 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

text: female

characteristic: sex

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone


text: MR

characteristic: External Id

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC secondary accession

text: live

text: Human

text: multiple myeloma

text: II

text: CD138+ cells from patient ID BOSTON_077 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

text: male

text: bone marrow

characteristic: tissue

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone


text: VGPR

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC center name

characteristic: INSDC first public

text: live

text: Human

text: multiple myeloma

text: II

text: CD138+ cells from patient ID BOSTON_078 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

text: male

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone

characteristic: treatment


text: SD

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC last update

text: live

characteristic: INSDC status

text: Human

text: multiple myeloma

text: II

text: CD138+ cells from patient ID BOSTON_079 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

characteristic: organism

text: female

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone


text: PR

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

characteristic: RIN

characteristic: age

text: multiple myeloma

text: II

text: CD138+ cells from patient ID BOSTON_080 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

text: female

text: bone marrow

text: Human sample from Homo sapiens

characteristic: title

text: selinexor + bortezomib + dexamethasone


text: VGPR

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

text: Smart-Seq V4 Ultra Low Input Nextera XT

text: multiple myeloma

characteristic: disease

text: II

text: CD138+ cells from patient ID BOSTON_081 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

text: female

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone


text: PR

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

characteristic: SRA accession

characteristic: batch

text: multiple myeloma

text: II

text: CD138+ cells from patient ID BOSTON_082 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

characteristic: isolate

text: Homo sapiens

text: female

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone


text: PR

characteristic: External Id

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC secondary accession

text: live

text: Human

text: multiple myeloma

text: II

text: CD138+ cells from patient ID BOSTON_083 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

text: male

characteristic: sex

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone


text: sCR

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC center name

characteristic: INSDC first public

text: live

text: Human

text: multiple myeloma

text: I

text: CD138+ cells from patient ID BOSTON_084 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

text: female

text: bone marrow

characteristic: tissue

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone


text: PR

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC last update

text: live

characteristic: INSDC status

text: Human

text: multiple myeloma

text: III

text: CD138+ cells from patient ID BOSTON_085 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

text: male

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone

characteristic: treatment


text: PR

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

characteristic: RIN

text: Smart-Seq V4 Ultra Low Input Nextera XT

characteristic: age

text: multiple myeloma

text: I

text: CD138+ cells from patient ID BOSTON_086 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

characteristic: organism

text: male

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone


text: PR

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

text: Smart-Seq V4 Ultra Low Input Nextera XT

text: multiple myeloma

text: III

text: CD138+ cells from patient ID BOSTON_087 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

text: male

text: bone marrow

text: Human sample from Homo sapiens

characteristic: title

text: selinexor + bortezomib + dexamethasone


text: VGPR

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

text: Smart-Seq V4 Ultra Low Input Nextera XT

characteristic: SRA accession

characteristic: batch

text: multiple myeloma

characteristic: disease

text: I

text: CD138+ cells from patient ID BOSTON_088 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

text: female

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone


text: PR

characteristic: External Id

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC secondary accession

text: live

text: Human

text: TruSeq Stranded mRNA (non-FFPE compatible)

text: multiple myeloma

text: II

text: CD138+ cells from patient ID BOSTON_089 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

characteristic: isolate

text: Homo sapiens

text: female

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone


text: PR

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC center name

characteristic: INSDC first public

text: live

text: Human

text: Smart-Seq V4 Ultra Low Input Nextera XT

text: Parekh Lab, Icahn School of Medicine at Mount Sinai

text: multiple myeloma

text: II

text: CD138+ cells from patient ID BOSTON_090 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

text: female

characteristic: sex

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone


text: VGPR

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC last update

text: live

characteristic: INSDC status

text: Human

text: Smart-Seq V4 Ultra Low Input Nextera XT

text: multiple myeloma

text: II

text: CD138+ cells from patient ID BOSTON_091 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

text: male

text: bone marrow

characteristic: tissue

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone


text: MR

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

characteristic: RIN

characteristic: age

text: multiple myeloma

text: I

text: CD138+ cells from patient ID BOSTON_092 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

text: male

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone

characteristic: treatment


text: CR

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

text: multiple myeloma

text: II

text: CD138+ cells from patient ID BOSTON_093 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

characteristic: organism

text: male

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone


text: SD

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

characteristic: SRA accession

characteristic: batch

text: multiple myeloma

text: I

text: CD138+ cells from patient ID BOSTON_094 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

text: female

text: bone marrow

text: Human sample from Homo sapiens

characteristic: title

text: selinexor + bortezomib + dexamethasone


text: PR

characteristic: External Id

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC secondary accession

text: live

text: Human

text: multiple myeloma

characteristic: disease

text: I

text: CD138+ cells from patient ID BOSTON_095 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

text: male

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone


text: VGPR

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC center name

characteristic: INSDC first public

text: live

text: Human

text: multiple myeloma

text: I

text: CD138+ cells from patient ID BOSTON_096 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

characteristic: isolate

text: Homo sapiens

text: female

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone


text: VGPR

text: Icahn School of Medicine at Mount Sinai

characteristic: INSDC last update

text: live

characteristic: INSDC status

text: Human

text: multiple myeloma

text: III

text: CD138+ cells from patient ID BOSTON_097 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

text: male

characteristic: sex

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone


text: PR

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

characteristic: RIN

characteristic: age

text: multiple myeloma

text: III

text: CD138+ cells from patient ID BOSTON_098 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

text: male

text: bone marrow

characteristic: tissue

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone


text: VGPR

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

text: multiple myeloma

text: II

text: CD138+ cells from patient ID BOSTON_099 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

text: female

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone

characteristic: treatment


text: PD

text: Icahn School of Medicine at Mount Sinai

text: live

text: Human

characteristic: SRA accession

characteristic: batch

text: multiple myeloma

text: I

text: CD138+ cells from patient ID BOSTON_100 who participated in the BOSTON study and recieved selinexor + bortezomib + dexamethasone

text: Homo sapiens

characteristic: organism

text: female

text: bone marrow

text: Human sample from Homo sapiens

text: selinexor + bortezomib + dexamethasone